Signal transduction

TGF Beta Receptor Type 1 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com

Friday, April 3, 2020 - 3:04pm

The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • TGF Beta Receptor Type 1 pipeline Target constitutes close to 17 molecules.
  • This report outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.

Global TGF Beta Receptor Type 1 Pipeline Insights, 2020: Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Dormant Products, Discontinued Products

Thursday, April 2, 2020 - 6:15pm

DUBLIN, April 2, 2020 /PRNewswire/ -- The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 2, 2020 /PRNewswire/ -- The "TGF Beta Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • TGF Beta Receptor Type 1 pipeline Target constitutes close to 17 molecules.
  • This report outlays comprehensive information on the TGF Beta Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.

Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology

Monday, March 30, 2020 - 6:42pm

The article, Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements was published online today in Cell Chemical Biology .

Key Points: 
  • The article, Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements was published online today in Cell Chemical Biology .
  • The article describes Surrozens Wnt-mimetic platform comprising potent, multivalent antibodies directly activating the Wnt signaling pathway.
  • The article will appear in print in a future issue of Cell Chemical Biology.
  • Investors/Partners: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. reza@surrozen.com Media: Denise Powell Red House Consulting denise@redhousecomms.com

Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

Monday, March 30, 2020 - 2:49pm

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
  • Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Thursday, March 26, 2020 - 8:01am

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

Thursday, March 19, 2020 - 8:05pm

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

Thursday, March 19, 2020 - 6:00pm

This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.

Key Points: 
  • This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.
  • Although GCGR couples to both G proteins through the common pocket, it does so with different interaction patterns, which account for G protein specificity.
  • Based on the structures of GCGR-G protein complexes, the researchers performed extensive functional studies using techniques such as mutagenesis, G protein activation and cell signaling to investigate the roles of key residues in the receptor-G protein binding interface in Gs and Gi activation.
  • The results show that conformational differences of intracellular loops and residue side chains in the receptor are sufficient to guide G protein selectivity.

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

Thursday, March 19, 2020 - 6:00pm

This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.

Key Points: 
  • This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.
  • Although GCGR couples to both G proteins through the common pocket, it does so with different interaction patterns, which account for G protein specificity.
  • Based on the structures of GCGR-G protein complexes, the researchers performed extensive functional studies using techniques such as mutagenesis, G protein activation and cell signaling to investigate the roles of key residues in the receptor-G protein binding interface in Gs and Gi activation.
  • The results show that conformational differences of intracellular loops and residue side chains in the receptor are sufficient to guide G protein selectivity.

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

Friday, March 6, 2020 - 12:00pm

VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.

Key Points: 
  • VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.
  • Palvella also intends to initiate an open-label extension program where patients will have the option to continue to receive study drug.
  • PTX-022 is supported by multiple issued method-of-use patents in the U.S. broadly covering the use of mTOR inhibitors in pachyonychia congenita.
  • Palvellas lead program, PTX-022 (QTORIN 3.9% rapamycin anhydrous gel), is in Phase 2/3 development for pachyonychia congenita, a rare, chronically debilitating and lifelong genetic disease.

BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

Thursday, March 5, 2020 - 12:00pm

BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases.

Key Points: 
  • BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases.
  • The company expects to report data from the proof of concept study in PNH patients in the second quarter of 2020.
  • Because Factor D is essential for alternative pathway overactivity in PNH, and all other complement diseases of the alternative pathway, successful proof of concept data with BCX9930 would enable BioCryst to advance the program across other target indications.
  • In this proof of concept study of the safety and effectiveness of oral BCX9930, up to 16 PNH patients will receive BCX9930 twice daily (BID) for 28 days.